BCL2L1 and Thrombocytopenia: Using safe-gated AND-logic between TIS senomarkers, SASP-inducible promoters, and degron-tuned BH3 payloads could minimize off-tumor BCL-xL antagonism and mitigate thrombocytopenia associated with systemic BCL-xL blockade.